Cargando…
Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients
There is growing evidence that chronic kidney disease (CKD) is an independent risk factor for cognitive impairment, especially due to vascular damage, blood–brain barrier disruption and uremic toxins. Given the presence of multiple comorbidities, the medication regimen of CKD patients often becomes...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689198/ https://www.ncbi.nlm.nih.gov/pubmed/38046029 http://dx.doi.org/10.1093/ckj/sfad239 |
_version_ | 1785152321072660480 |
---|---|
author | Hafez, Gaye Malyszko, Jolanta Golenia, Aleksandra Klimkowicz-Mrowiec, Aleksandra Ferreira, Ana Carina Arıcı, Mustafa Bruchfeld, Annette Nitsch, Dorothea Massy, Ziad A Pépin, Marion Capasso, Giovambattista Mani, Laila-Yasmin Liabeuf, Sophie |
author_facet | Hafez, Gaye Malyszko, Jolanta Golenia, Aleksandra Klimkowicz-Mrowiec, Aleksandra Ferreira, Ana Carina Arıcı, Mustafa Bruchfeld, Annette Nitsch, Dorothea Massy, Ziad A Pépin, Marion Capasso, Giovambattista Mani, Laila-Yasmin Liabeuf, Sophie |
author_sort | Hafez, Gaye |
collection | PubMed |
description | There is growing evidence that chronic kidney disease (CKD) is an independent risk factor for cognitive impairment, especially due to vascular damage, blood–brain barrier disruption and uremic toxins. Given the presence of multiple comorbidities, the medication regimen of CKD patients often becomes very complex. Several medications such as psychotropic agents, drugs with anticholinergic properties, GABAergic drugs, opioids, corticosteroids, antibiotics and others have been linked to negative effects on cognition. These drugs are frequently included in the treatment regimen of CKD patients. The first review of this series described how CKD could represent a risk factor for adverse drug reactions affecting the central nervous system. This second review will describe some of the most common medications associated with cognitive impairment (in the general population and in CKD) and describe their effects. |
format | Online Article Text |
id | pubmed-10689198 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-106891982023-12-02 Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients Hafez, Gaye Malyszko, Jolanta Golenia, Aleksandra Klimkowicz-Mrowiec, Aleksandra Ferreira, Ana Carina Arıcı, Mustafa Bruchfeld, Annette Nitsch, Dorothea Massy, Ziad A Pépin, Marion Capasso, Giovambattista Mani, Laila-Yasmin Liabeuf, Sophie Clin Kidney J CKJ Review There is growing evidence that chronic kidney disease (CKD) is an independent risk factor for cognitive impairment, especially due to vascular damage, blood–brain barrier disruption and uremic toxins. Given the presence of multiple comorbidities, the medication regimen of CKD patients often becomes very complex. Several medications such as psychotropic agents, drugs with anticholinergic properties, GABAergic drugs, opioids, corticosteroids, antibiotics and others have been linked to negative effects on cognition. These drugs are frequently included in the treatment regimen of CKD patients. The first review of this series described how CKD could represent a risk factor for adverse drug reactions affecting the central nervous system. This second review will describe some of the most common medications associated with cognitive impairment (in the general population and in CKD) and describe their effects. Oxford University Press 2023-09-18 /pmc/articles/PMC10689198/ /pubmed/38046029 http://dx.doi.org/10.1093/ckj/sfad239 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the ERA. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | CKJ Review Hafez, Gaye Malyszko, Jolanta Golenia, Aleksandra Klimkowicz-Mrowiec, Aleksandra Ferreira, Ana Carina Arıcı, Mustafa Bruchfeld, Annette Nitsch, Dorothea Massy, Ziad A Pépin, Marion Capasso, Giovambattista Mani, Laila-Yasmin Liabeuf, Sophie Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients |
title | Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients |
title_full | Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients |
title_fullStr | Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients |
title_full_unstemmed | Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients |
title_short | Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients |
title_sort | drugs with a negative impact on cognitive functions (part 2): drug classes to consider while prescribing in ckd patients |
topic | CKJ Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689198/ https://www.ncbi.nlm.nih.gov/pubmed/38046029 http://dx.doi.org/10.1093/ckj/sfad239 |
work_keys_str_mv | AT hafezgaye drugswithanegativeimpactoncognitivefunctionspart2drugclassestoconsiderwhileprescribinginckdpatients AT malyszkojolanta drugswithanegativeimpactoncognitivefunctionspart2drugclassestoconsiderwhileprescribinginckdpatients AT goleniaaleksandra drugswithanegativeimpactoncognitivefunctionspart2drugclassestoconsiderwhileprescribinginckdpatients AT klimkowiczmrowiecaleksandra drugswithanegativeimpactoncognitivefunctionspart2drugclassestoconsiderwhileprescribinginckdpatients AT ferreiraanacarina drugswithanegativeimpactoncognitivefunctionspart2drugclassestoconsiderwhileprescribinginckdpatients AT arıcımustafa drugswithanegativeimpactoncognitivefunctionspart2drugclassestoconsiderwhileprescribinginckdpatients AT bruchfeldannette drugswithanegativeimpactoncognitivefunctionspart2drugclassestoconsiderwhileprescribinginckdpatients AT nitschdorothea drugswithanegativeimpactoncognitivefunctionspart2drugclassestoconsiderwhileprescribinginckdpatients AT massyziada drugswithanegativeimpactoncognitivefunctionspart2drugclassestoconsiderwhileprescribinginckdpatients AT pepinmarion drugswithanegativeimpactoncognitivefunctionspart2drugclassestoconsiderwhileprescribinginckdpatients AT capassogiovambattista drugswithanegativeimpactoncognitivefunctionspart2drugclassestoconsiderwhileprescribinginckdpatients AT manilailayasmin drugswithanegativeimpactoncognitivefunctionspart2drugclassestoconsiderwhileprescribinginckdpatients AT liabeufsophie drugswithanegativeimpactoncognitivefunctionspart2drugclassestoconsiderwhileprescribinginckdpatients AT drugswithanegativeimpactoncognitivefunctionspart2drugclassestoconsiderwhileprescribinginckdpatients |